drugset / Trial / NCT01084174
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peanut extract | Unknown | 3.7 mg | Other |
| Subject | Peanut powder | Unknown | 2000 mg | Oral |